The U.S. Food and Drug Administration has requested additional data from Eli Lilly regarding its newly approved obesity pill, Foundayo, which can reduce body weight by 11% over 72 weeks. The FDA has also requested that Lilly conduct post-marketing trials to assess risks of cardiovascular events and delayed gastric emptying. The drugmaker is already conducting a trial comparing the pill with insulin glargine in participants with type 2 diabetes and obesity who are at increased cardiovascular risk.